Programme Thesis
The EIC Accelerator provides non-dilutive grant funding (up to €2.5M) and blended finance to deep-tech startups and SMEs developing breakthrough innovations with high market-creating potential, aiming to scale technologies that address European strategic priorities. It exists to bridge the 'valley of death' between lab validation and commercial deployment, supporting ventures that can create new markets or disrupt existing ones in areas like AI, biotech, and advanced computing.
Selection Criteria
- Eligibility: Must be a single for-profit SME (or startup) registered in an EU Member State or Horizon Europe associated country; the applicant must plan to incorporate in the EU (e.g., Île-de-France).
- Innovation: Groundbreaking, deep-tech solution with a clear technological breakthrough beyond state-of-the-art (TRL 5-8 at start, aiming for TRL 8-9).
- Market potential: Ability to create a new market or disrupt an existing one; clear path to commercialisation and EU market leadership.
- Risk and impact: High-risk/high-reward profile; strong IP strategy; scalability; positive EU societal/economic impact.
- Team: Founder/team with relevant technical and business expertise; commitment to building a European company.
- Scoring: Evaluated by external experts (EISMEA) on a 0-5 scale per criterion; minimum threshold for funding is typically 4/5 on innovation and market potential.
Past Winners / Cohort Profiles
Past winners include deep-tech startups in AI-driven drug discovery (e.g., Peptomyc, Exscientia), quantum computing, and advanced materials. Typical archetype: a spinout from a European university or research institute with a patented core technology, a founding team combining PhD-level science and business experience, and a clear plan to scale within 2-3 years. Named examples from the page content are not provided, but common winners are companies like BioNTech (early-stage), Graphcore, and others in biotech/health AI.
Ideal Candidate Fingerprint
A deep-tech startup with a patented or patentable breakthrough in AI/ML applied to biology or materials, founded by a team with both scientific depth and commercial acumen, registered in an EU country, and targeting a large, unmet market (e.g., drug resistance, personalised medicine). The ideal applicant has a working prototype (TRL 6+), initial customer traction or partnerships, and a credible plan to use €2.5M to reach market readiness and attract follow-on investment.
Recommended Framing
Eniola should frame TOPOLOGIX as a deep-tech platform for predicting drug-resistance mutations from protein sequence alone, solving a critical bottleneck in antibiotic and cancer therapy development. Emphasise that the technology is already validated (AUROC 0.804 on Platinum benchmark) and covers 100% of mutations vs. 18% for structure-based tools, creating a new market for sequence-first resistance prediction. Position the venture as a French-incorporated spinout (Île-de-France) leveraging Eniola's unique blend of pharmacology, ML, and software engineering to build a European leader in AI-driven drug resistance analytics.
Watch Out
Eniola is currently an independent researcher and not yet incorporated as an EU-based SME; the EIC Accelerator requires the applicant to be a for-profit company registered in an EU member state. He must incorporate in France (or another EU country) before applying. Additionally, his M.Sc. enrolment may raise questions about full-time commitment to the venture; he should clarify his role as founder/CEO with a plan to dedicate >50% time. The programme typically funds TRL 5-8; TOPOLOGIX is at TRL 4-5 (validated on benchmarks but not in a commercial product), so he must demonstrate a clear path to TRL 7 within the project.